Treatment of Age-Related Macular Degeneration With Anecortave Acetate
This study has been completed.
Information provided by (Responsible Party):
Joan, Manhattan Eye, Ear & Throat Hospital
First received: September 13, 2005
Last updated: October 24, 2012
Last verified: October 2012
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
Drug: Anecortave Acetate Sterile Suspension (15 mg)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2007 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||50 Years and older
|Genders Eligible for Study:
- Clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using Visudyne.
- Patients must be at least 50 years of age.
- Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart
- Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart
- Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
- Patients who have undergone intraocular surgery within the last 2 months.
- Patient participating in any other investigational drug study.
- Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
- Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access).
- Patient with significant liver disease or uremia.
- Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
- Patient has a history of any medical condition which would preclude scheduled visits or completion of study
- Patient has had insertion of scleral buckle in the study eye
- Patient has received radiation treatment
- Patient is on anticoagulant therapy with the exception of aspirin
- Patient is pregnant or nursing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00211458
|Manhattan Eye, Ear & Throat Hospital
|New York, New York, United States, 10021 |
Manhattan Eye, Ear & Throat Hospital
||Jason S Slakter, MD
||Manhattan Eye, Ear & Throat Hospital
No publications provided
||Joan, Jason Slakter, M.D., Manhattan Eye, Ear & Throat Hospital
History of Changes
|Other Study ID Numbers:
||Failed PDT treated with AA
|Study First Received:
||September 13, 2005
||October 24, 2012
||United States: Food and Drug Administration
Keywords provided by Manhattan Eye, Ear & Throat Hospital:
Age-Related Macular Degeneration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 14, 2014
Angiogenesis Modulating Agents
Physiological Effects of Drugs